Document:

Form of Warrant

  
 EXHIBIT 4.1 
  
 SPECTRUM PHARMACEUTICALS, INC. 
  
 WARRANT

  
 
	 Dated: January 16, 2003
 	 	 Number SPPIXXX
 

 
  
 Spectrum Pharmaceuticals, Inc., a Delaware corporation (the
“Company”), hereby certifies that, for value received,                          or its registered assigns
(“Holder”), is entitled, subject to the terms set forth below, to purchase from the Company up to a total of                  shares of Common
Stock, $.001 par value per share (the “Common Stock”), of the Company (each such share, a “Warrant Share” and all such shares, the “Warrant Shares”) at an exercise price equal to $3.25 per share (as
adjusted from time to time as provided in Section 7, the “Exercise Price”), at any time and from time to time from and after the date hereof and through and including January 16, 2008 (the “Expiration Date”), and subject
to the following terms and conditions: 
  
 1.    Registration of
Warrant.    The Company shall register this Warrant upon records to be maintained by the Company for that purpose (the “Warrant Register”), in the name of the record Holder hereof from time to time. The Company may
deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, and the Company shall not be affected by notice to the contrary.

  
 2.    Registration of Transfers and Exchanges. 
  
 (a)    This Warrant may not be sold, transferred, assigned pledged, hypothecated or otherwise disposed, directly or
indirectly, in whole or in part, without the prior written consent of the Company. Any attempted sale, transfer, assignment, pledge, hypothecation or other disposition of this Warrant, or any portion thereof, shall be void and without any force or
effect; provided, however, that, subject to compliance with any applicable securities laws, the Holder may transfer this Warrant, or any portion thereof, without the prior written consent of the Company, if such transfer is to (i) a spouse, child,
grandchild, parent, sibling or custodian or trustee for the benefit of any such relatives, or (ii) any shareholder or affiliate entity. 
  
 (b)    The Company shall register the transfer of any portion of this Warrant in conformance with Section 2(a) in the Warrant Register, upon surrender of this Warrant, with the Form of Assignment attached
hereto duly completed and signed, to the Company at the office specified in or pursuant to Section 10. Upon any such registration or transfer, a new warrant to purchase Common Stock, in substantially the form of this Warrant (any such new warrant, a
“New Warrant”), evidencing the portion of this Warrant so transferred shall be issued to the transferee and a New Warrant evidencing the remaining portion of this Warrant not so transferred, if any, shall be issued to the
transferring Holder. The acceptance of the New Warrant by the transferee thereof shall be deemed the acceptance of such transferee of all of the rights and obligations of a holder of this Warrant. 

  
 (c)    This Warrant is exchangeable, upon the surrender
hereof by the Holder to the office of the Company specified in or pursuant to Section 10 for one or more New Warrants, evidencing in the aggregate the right to purchase the number of Warrant Shares which may then be purchased hereunder.

  
 3.    Duration and Exercise of Warrant. 
  
 (a)    This Warrant shall be exercisable by the then registered Holder on any business day before 5:00 P.M.,
California time, at any time and from time to time on or after the date hereof to and including the Expiration Date. At 5:00 P.M., California time on the Expiration Date, the portion of this Warrant not exercised prior thereto shall be and become
void and of no value. 
  
 (b)    Upon surrender of this Warrant, with the Form of Election to
Purchase attached hereto duly completed and signed, to the Company at its address for notice set forth in Section 10 and upon payment of the Exercise Price multiplied by the number of Warrant Shares that the Holder intends to purchase hereunder, in
the manner provided hereunder, all as specified by the Holder in the Form of Election to Purchase, the Company shall promptly (and in any event, within four business days) issue or cause to be issued and cause to be delivered to or upon the written
order of the Holder and in such name or names as the Holder may designate, a certificate for the Warrant Shares issuable upon such exercise. Any person so designated by the Holder to receive Warrant Shares shall be deemed to have become holder of
record of such Warrant Shares as of the Date of Exercise of this Warrant. 
  
 A “Date of Exercise” means
the date on which the Company shall have received (i) this Warrant (or any New Warrant, as applicable), with the Form of Election to Purchase attached hereto (or attached to such New Warrant) appropriately completed and duly signed, and (ii) payment
of the Exercise Price for the number of Warrant Shares so indicated by the holder hereof to be purchased. 
  
 (c)    This Warrant shall be exercisable, either in its entirety or, from time to time, for a portion of the number of Warrant Shares. If less than all of the Warrant Shares which may be purchased under this
Warrant are exercised at any time, the Company shall issue or cause to be issued, at its expense, a New Warrant evidencing the right to purchase the remaining number of Warrant Shares for which no exercise has been evidenced by this Warrant.

  
 (d)    Prior to the exercise of this Warrant, the Holder shall not be entitled to any rights
as a stockholder of the Company with respect to the Warrant Shares, including (without limitation) the right to vote such shares, receive dividends or other distributions thereon or be notified of stockholder meetings (except as otherwise set forth
in Section 7(f) herein). 
  
 (e)    If by the tenth business day after a Date of Exercise the
Company fails to deliver the required number of Warrant Shares in the manner required pursuant to Section 3(b), then the Holder will have the right to rescind such exercise. 
  
 (f)    The Company’s obligations to issue and deliver Warrant Shares in accordance with the terms hereof are absolute and unconditional,
irrespective of any action or inaction by the Holder to enforce the same, any waiver or consent with respect to any provision 

  
 hereof, the recovery of any judgment against any Person or any action to enforce the same, or any
setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder or any other Person of any obligation to the Company or any violation or alleged violation of law by the Holder or any other Person, and
irrespective of any other circumstance which might otherwise limit such obligation of the Company to the Holder in connection with the issuance of Warrant Shares. Nothing herein shall limit a Holder’s right to pursue any other remedies
available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver certificates representing shares of Common Stock
upon exercise of the Warrant as required pursuant to the terms hereof. 
  
 4.    Payment of
Taxes.    The Company will pay any documentary stamp taxes attributable to the issuance of Warrant Shares upon the exercise of this Warrant; provided, however, that the Company shall not be required to pay any tax which may
be payable in respect of any transfer involved in the registration of any certificates for Warrant Shares or Warrants in a name other than that of the Holder. The Holder shall be responsible for all other tax liability that may arise as a result of
holding or transferring this Warrant or receiving Warrant Shares upon exercise hereof. 
  
 5.    Replacement of Warrant.    If this Warrant is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon
cancellation hereof, or in lieu of and substitution for this Warrant, a New Warrant, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction and indemnity, if requested, satisfactory to it.
Applicants for a New Warrant under such circumstances shall also comply with such other reasonable regulations and procedures and pay such other reasonable charges as the Company may prescribe. 
  

6.    Reservation of Warrant Shares.    The Company covenants that it will at all times reserve and keep available out
of the aggregate of its authorized but unissued Common Stock, solely for the purpose of enabling it to issue Warrant Shares upon exercise of this Warrant as herein provided, the number of Warrant Shares which are then issuable and deliverable upon
the exercise of this entire Warrant, free from preemptive rights or any other actual contingent purchase rights of persons other than the Holder. The Company covenants that all Warrant Shares that shall be so issuable and deliverable shall, upon
issuance and the payment of the applicable Exercise Price in accordance with the terms hereof, be duly authorized, validly issued and fully paid and nonassessable. 
  
 7.    Certain Adjustments.    The Exercise Price and number of Warrant Shares issuable upon exercise of this Warrant are
subject to adjustment from time to time as set forth in this Section 7. Upon each such adjustment of the Exercise Price pursuant to this Section 7, the Holder shall thereafter prior to the Expiration Date be entitled to purchase, at the Exercise
Price resulting from such adjustment, the number of Warrant Shares obtained by multiplying the Exercise Price in effect immediately prior to such adjustment by the number of Warrant Shares issuable upon exercise of this Warrant immediately prior to
such adjustment and dividing the product thereof by the Exercise Price resulting from such adjustment. 

  
 (a)    If the Company, at any time while this Warrant is
outstanding, (i) shall pay a stock dividend (except scheduled dividends paid on outstanding preferred stock which contain a stated dividend rate) or otherwise make a distribution or distributions on shares of its Common Stock payable in shares of
Common Stock, (ii) subdivide outstanding shares of Common Stock into a larger number of shares, or (iii) combine outstanding shares of Common Stock into a smaller number of shares, the Exercise Price shall be multiplied by a fraction of which the
numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding before such event and the denominator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding after such
event. Any adjustment made pursuant to this Section shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the
effective date in the case of a subdivision or combination, and shall apply to successive subdivisions and combinations. 
  
 (b)    In case of any reclassification of the Common Stock, any consolidation or merger of the Company with or into another person, the sale or transfer of all or substantially all of the assets of the Company or
any compulsory share exchange pursuant to which the Common Stock is converted into other securities, cash or property, then the Holder shall have the right thereafter to exercise this Warrant only into the shares of stock and other securities and
property receivable upon or deemed to be held by holders of Common Stock following such reclassification, consolidation, merger, sale, transfer or share exchange, and the Holder shall be entitled upon such event to receive such amount of securities
or property equal to the amount of Warrant Shares such Holder would have been entitled to had such Holder exercised this Warrant immediately prior to such reclassification, consolidation, merger, sale, transfer or share exchange. The terms of any
such consolidation, merger, sale, transfer or share exchange shall include such terms so as to continue to give to the Holder the right to receive the securities or property set forth in this Section 7(b) upon any exercise following any such
reclassification, consolidation, merger, sale, transfer or share exchange. 
  
 (c)    If the
Company, at any time while this Warrant is outstanding, shall distribute to all holders of Common Stock (and not to holders of this Warrant) evidences of its indebtedness or assets or rights or warrants to subscribe for or purchase any security
(excluding those referred to in Sections 7(a), and (b)), other than as part of its dissolution or liquidation or the winding up of its affairs, then in each such case the Exercise Price shall be determined by multiplying the Exercise Price in effect
immediately prior to the record date fixed for determination of stockholders entitled to receive such distribution by a fraction of which the denominator shall be the fair market value of a share of Common Stock determined as of the record date
mentioned above, and of which the numerator shall be the fair market value of a share of Common Stock determined as of such record date less the fair market value at such record date of the portion of such assets or evidence of indebtedness so
distributed applicable to one outstanding share of Common Stock as determined by the Company’s independent certified public accountants that regularly examines the financial statements of the Company (an “Appraiser”). 

 
 (d)    For the purposes of this Section 7, the following clauses shall also be applicable: 

  

	 	    (i)
	 
	Record Date.    In case the Company shall take a record of the holders of its Common Stock for the purpose of entitling them (A) to
receive a dividend or other distribution payable in Common Stock or in securities convertible or exchangeable into shares of Common Stock, or (B) to subscribe for or purchase Common Stock or securities convertible or exchangeable into shares of
Common Stock, then such record date shall be deemed to be the date of the issue or sale of the shares of Common Stock deemed to have been issued or sold upon the declaration of such dividend or the making of such other distribution or the date of
the granting of such right of subscription or purchase, as the case may be. 
 

  

	 	    (ii)
	 
	Treasury Shares.    The number of shares of Common Stock outstanding at any given time shall not include shares owned or held by or
for the account of the Company, and the disposition of any such shares shall be considered an issue or sale of Common Stock. 
 

  
 (e)    All calculations under this Section 7 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. 
  
 (f)    If: 
  

	 	    (i)
	 
	the Company shall declare a dividend (or any other distribution) on its Common Stock; or 
 

  

	 	    (ii)
	 
	the Company shall declare a special nonrecurring cash dividend on or a redemption of its Common Stock; or 
 

  

	 	    (iii)
	 
	the Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any
class or of any rights; or 
 

  

	 	    (iv)
	 
	the approval of any stockholders of the Company shall be required in connection with any reclassification of the Common Stock of the Company, any consolidation
or merger to which the Company is a party, any sale or transfer of all or substantially all of the assets of the Company, or any compulsory share exchange whereby the Common Stock is converted into other securities, cash or property; or

 

  

	 	    (v)
	 
	the Company shall authorize the voluntary dissolution, liquidation or winding up of the affairs of the Company, 
 

  
 then the Company shall cause to be mailed to each Holder at their last addresses as they shall appear upon the Warrant Register, at least 30 calendar days prior
to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not 

  
 to be taken, the date as of which the holders of Common Stock of record to be entitled to such dividend,
distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is
expected that holders of Common Stock of record shall be entitled to exchange their shares of Common Stock for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer, share exchange,
dissolution, liquidation or winding up; provided, however, that the failure to mail such notice or any defect therein or in the mailing thereof shall not affect the validity of the corporate action required to be specified in such notice.

  
 8.    Payment of Exercise Price.    The Holder shall pay the
Exercise Price in immediately available funds by certified check or bank draft payable to the order of the Company or by wire transfer to an account designated by the Company. 
  
 9.    Fractional Shares.    The Company shall not be required to issue or cause to be issued fractional Warrant Shares on the
exercise of this Warrant. The number of full Warrant Shares which shall be issuable upon the exercise of this Warrant shall be computed on the basis of the aggregate number of Warrant Shares purchasable on exercise of this Warrant so presented. If
any fraction of a Warrant Share would, except for the provisions of this Section 9, be issuable on the exercise of this Warrant, the Company shall pay an amount in cash equal to the Exercise Price multiplied by such fraction. 

 
 10.    Notices.    Any and all notices or other communications or deliveries
hereunder shall be in writing and shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice or communication is delivered via facsimile at the facsimile telephone number specified in this Section prior to
5:00 p.m. (California time) on a business day, (ii) the business day after the date of transmission, if such notice or communication is delivered via facsimile at the facsimile telephone number specified in this Section later than 5:00 p.m.
(California time) on any date and earlier than 11:59 p.m. (California time) on such date, (iii) the business day following the date of mailing, if sent by nationally recognized overnight courier service, or (iv) upon actual receipt by the party to
whom such notice is required to be given. The addresses for such communications shall be: (i) if to the Company, to 157 Technology Drive, Irvine, CA 92618, Attention: Vice President Finance, or to facsimile no. (949) 788-6706, or (ii) if to the
Holder, to the Holder at the address or facsimile number appearing on the Warrant Register or such other address or facsimile number as the Holder may provide to the Company in accordance with this Section 10. 
  
 11.    Warrant Agent.    The Company shall serve as warrant agent under this Warrant. The
Company may appoint a new warrant agent upon notice to the Holder in accordance with Section 10. Any corporation into which the Company may be merged or any corporation resulting from any consolidation to which the Company shall be a party or any
corporation to which the Company transfers substantially all of its corporate assets shall be a successor warrant agent under this Warrant without any further act. Any such successor warrant agent shall promptly cause notice of its succession as
warrant agent to be mailed (by first class mail, postage prepaid) to the Holder at the Holder’s last address as shown on the Warrant Register. 

  
 12.    Miscellaneous. 
  
 (a)    This Warrant shall be binding on and inure to the benefit of the parties hereto and their respective successors
and permitted assigns. This Warrant may be amended only in writing signed by the Company and the Holder and their successors and assigns. 
  
 (b)    Subject to Section 12(a), above, nothing in this Warrant shall be construed to give to any person or corporation other than the Company and the Holder any legal or equitable right, remedy or cause
under this Warrant. This Warrant shall inure to the sole and exclusive benefit of the Company and the Holder. 
  
 (c)    This Warrant shall be governed by and construed and enforced in accordance with the internal laws of the State of California without regard to the principles of conflicts of law thereof. The Company and the
Holder hereby irrevocably submit to the exclusive jurisdiction of the state and federal courts sitting in Orange County, California, for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby
or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, or that such suit, action or proceeding is improper.
Each of the Company and the Holder hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by receiving a copy thereof sent to it at the address in effect for notices to it
under this instrument and in the manner set forth in Section 10 above, and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to
serve process in any manner permitted by law. 
  
 (d)    The headings herein are for convenience
only, do not constitute a part of this Warrant and shall not be deemed to limit or affect any of the provisions hereof. 
  
 (e)    In case any one or more of the provisions of this Warrant shall be invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Warrant shall not in
any way be affected or impaired thereby and the parties will attempt in good faith to agree upon a valid and enforceable provision which shall be a commercially reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute
provision in this Warrant. 

  
 IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by
its authorized officer as of the date first indicated above. 
  
 
	 SPECTRUM PHARMACEUTICALS, INC.
 
	 
	 By:
 	 	 /s/    Rajesh C. Shrotriya        
 

	 
	 Name:
 	 	 Rajesh C. Shrotriya, M.D.
 

	 
	 Title:
 	 	 Chief Executive Officer and President
 

 
  

  
 FORM OF ELECTION TO PURCHASE 
  
 (To be executed by the Holder to exercise the right to purchase shares of Common Stock under 
 the foregoing Warrant) 
  
 To Spectrum Pharmaceuticals, Inc.: 
  
 In accordance with the Warrant enclosed with this
Form of Election to Purchase, the undersigned hereby irrevocably elects to purchase                      shares of Common Stock (“Common
Stock”), $.001 par value per share, of Spectrum Pharmaceuticals, Inc. encloses herewith $                     in cash, certified or
official bank check or checks, which sum represents the aggregate Exercise Price (as defined in the Warrant) for the number of shares of Common Stock to which this Form of Election to Purchase relates, together with any applicable taxes payable by
the undersigned pursuant to the Warrant. 
  
 The undersigned requests that certificates for the shares of Common
Stock issuable upon this exercise be issued in the name of 
  
 PLEASE INSERT SOCIAL SECURITY OR

 TAX IDENTIFICATION NUMBER 
  
  
                                      
                                        
                                        
                           
  
  
                                      
                                        
                                        
                                        
                                        
                                        
                     
 (Please print name and address)

  
 If the number of shares of Common Stock issuable upon this exercise shall not be all of the shares of Common
Stock which the undersigned is entitled to purchase in accordance with the enclosed Warrant, the undersigned requests that a New Warrant (as defined in the Warrant) evidencing the right to purchase the shares of Common Stock not issuable pursuant to
the exercise evidenced hereby be issued in the name of and delivered to: 
  
                                      
                                        
                                        
                                        
                                        
                                        
                     
 (Please print name and address)

  
                                      
                                        
                                        
                                        
                                        
                                        
                     
  
                                      
                                        
                                        
                                        
                                        
                                        
                     

  
 
	 Dated:                      ,
        
 	 	  	 	 Name of Holder:
 
	 
	  	 	  	 	  	 	 (Print)                                    
                                        
                                  
 
	 
	  	 	  	 	  	 	 (By:)                                    
                                        
                                     
 
	 
	  	 	  	 	  	 	 (Name:)
 
	  	 	  	 	  	 	 (Title:)
 
	  	 	  	 	  	 	 (Signature must conform in all respects to name of
 holder as specified on the face of the Warrant)
 

 
  

  
 FORM OF ASSIGNMENT 
  
 [To be completed and signed only upon transfer of Warrant] 
  
 FOR VALUE RECEIVED, the undersigned hereby sells, assigns and transfers unto the
                                        
right represented by the Warrant enclosed with this Form of Assignment to purchase                      shares of Common Stock of Spectrum
Pharmaceuticals, Inc. to which the Warrant relates and appoints
                                        
attorney to transfer said right on the books of Spectrum Pharmaceuticals, Inc. with full power of substitution in the premises. 
  
 Dated:                     ,         

  
  
                                      
                                        
                                        
                           
 (Signature must conform in all respects to name of 
 holder as specified on the face of the Warrant)

  
  
                                      
                                        
                                        
                           
 Address of Transferee 
  
  
                                      
                                        
                                        
                           
  
                                      
                                        
                                        
                           
  
  
 
	 In the presence of:Securities Purchase Agreement

  
 EXHIBIT 10.1 
  
 SECURITIES PURCHASE AGREEMENT 
  
 This Securities Purchase
Agreement (the “Agreement”) is made as of January 16, 2003, by and between                         
  (“Purchaser”), and Spectrum Pharmaceuticals, Inc. (“Company”), whereby the parties agree as follows: 
  
 The Purchaser shall buy from the Company and the Company agrees to sell to the Purchaser: (i)
                         shares (the “Shares”) of the Company’s common stock, par value $.001 per share
(the “Common Stock”), at a price of $2.25 per share for an aggregate purchase price of                         
(the “Purchase Price”), and (ii) a five-year warrant to purchase up to                          shares of Common
Stock (the “Warrant”), at an exercise price of $3.25 per share, in the form attached hereto as Exhibit A. 
  
 The Company
warrants that as of January 16, 2003 there are 2,726,019 shares of common stock issued. 
  
 The Shares and the Warrant are being issued and
sold pursuant to a registration statement on Form S-3, File No. 333-53108, which registration statement has been declared effective by the Securities and Exchange Commission. The Company is delivering herewith a prospectus supplement on Form
424(b)(5) regarding the issuance and sale of the Shares and the Warrant prior to funding, a copy of which is attached hereto as Exhibit B. The Shares and Warrant are free of restrictive legends and the Shares and the shares of Common Stock
issuable upon exercise of the Warrant, when issued upon exercise of the Warrant in accordance with its terms and as described in the prospectus supplement, will be free of any resale restrictions. 
  
 Prior to the close of business on the date hereof: 
  

	 	1.
	 
	The Purchaser shall wire the Purchase Price to the Company to the account set forth below. 
 

  
 Company Wire Transfer Instructions: 
  
                                      
                                        
          
  
                                      
                                        
          
  
                                      
                                        
          
  

	 	2.
	 
	The Company shall (A) deliver a facsimile copy of the Warrant to the Purchaser at the address for notices set forth below, with the original Warrant to be
delivered to such address on the next following business day, and (B) cause its transfer agent to transmit the Shares electronically to the Purchaser by crediting the account set forth below through the Deposit Withdrawal Agent Commission system.

 

  
 Purchaser DWAC Instructions: 
  
 DTC No.                        

  
 Account
No.                                     

 
 Account
Name:                                       
      

 Notices to the Company shall be delivered to: 
  
 Spectrum Pharmaceuticals, Inc. 
 Attention: Rajesh Shrotriya, M.D.

 Chairman and Chief Executive Officer 
 157 Technology
Drive, 
 Irvine, California 92618 
 Facsimile: (949) 788-6706

  
 Notices to Purchaser shall be delivered to: 
  
                                      
                             
  
                                      
                             
  
                                      
                             
  
                                      
                             
  
 Delivery of an executed copy of a signature page to this Agreement by facsimile transmission shall be effective as delivery of a manually executed copy of this Agreement and shall be effective and
enforceable as the original. This Agreement shall be governed and construed in accordance with the internal laws of the State of California without giving effect to the conflicts of law principles thereunder. 
  
 AGREED AND ACCEPTED, as of the date indicated above: 
  
 Spectrum Pharmaceuticlas, Inc. 
  
 
	 
	 By:
 	 	             /s/  Rajesh Shrotriya
 

	 
	 Name:
 	 	             Rajesh Shrotriya, M.D.
 

	 
	 Ttle:
 	 	             Chief Executive Officer and President
 

 
 
	 
	  
  
  
 Purchaser Name:
 	 	  
  
  
  
 

 
 
	 
	 By:
 	 	  
 

	 
	 Name:
 	 	  
 

	 
	 Ttle:
 	 	  
 

 

  
 EXHIBIT A 

  
 EXHIBIT B 

  
 SCHEDULE 1 
 
	 Purchaser
 
	    	 Shares
 
	    	 Purchase
 Price
 
	    	 Warrant Shares
 

	 Cranshire Capital, LP
 	    	 88,889
 	    	 $200,000.25
 	    	 22,222
 
	 Omicron Master Trust
 	    	 88,889
 	    	 $200,000.25
 	    	 22,222
 
	 ICN Capital, Ltd.
 	    	 44,445
 	    	 $100,001.25
 	    	 11,111

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00046-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00046-of-00352.parquet"}]]